The Challenge: Understanding how KOLs define the treatment evolution and the unmet needs in multiple myeloma space.
Α large biopharma company asked LucidQuest to support them with KOLs insights into the multiple myeloma space, particularly around the treatment evolution and the unmet needs.
The action: Τargeted qualitative interviews with around 30 leading KOLs from the EU and the US
LucidQuest conducted focused qualitative interviews with around 30 leading multiple myeloma KOLs in the US and EU and gathered insights into their view of the current treatment paradigm and its future evolution.
The result: Informed asset development process and clinical trial design.
The biopharma company used LucidQuest findings on the KOLs’ views on the multiple myeloma treatment future, and insights into competitor company plans and activities to create its asset development process and clinical trial design (endpoint/outcomes selection).
#multiplemyeloma #hematology #KOLinsights #drugdevelopment #multiplemyelomatreatments #clinicaltrialdesign #casestudy #ourwork